Contents

SECTION 1 INTRODUCTION

1. Making of a Cardiologist **3**
AB Mehta

2. Heart Team: Concept and Utility **5**
Praveen Chandra, Rashmi Xavier, Manoj Dhanger, Rohit Goel, Naresh Trehan
Main Benefits *5*
Barriers *5*
Applications in Coronary Artery Disease *6*
Application in Transcutaneous Aortic Valve Implantation *6*
Composition *7*

3. Heart Transplantation: The Path Ahead **11**
Jose Chacko Periappuram, Rony Mathew, Jacob Abraham, Jo Joseph
The Indian Scenario *11*
Recipient Selection *11*
Donor Allocation and Selection *13*
Donor Acceptance *13*
Mechanical Circulatory Support *13*
Surgery of Heart Transplantation *14*
Immunosuppression *14*
Post-transplant Monitoring *15*
Challenges for Transplantation in India *15*

SECTION 2 HYPERTENSION AND DYSLIPIDEMIA

4. Heart Outcomes Prevention Evaluation-3 Trial: Implications in Primary Prevention in India **21**
Santanu Guha, Siddhartha Mani
Analysis of the Trial *21*
Implications of the Results *22*
Indian Perspective *22*

5. Implications of SPRINT Trial for Clinical Practice: A Realistic Approach **27**
SS Iyengar
What do the Guidelines Say? *27*
Summary of Sprint Trial *28*
Reports from Recent Studies *28*
Summary: What should we Follow? *28*

6. Blood Pressure Variability and its Significance **31**
Nagaraj Desai, Chilkunda Raviprakash Venkatesh, Sunil Kumar S, Prashant Kulkarni, Manjappa M
Short-term Variability *31*
Long-term Variability *33*

7. Work-up for Secondary Hypertension: When, why and how much? **37**
Praveen Jain, Mohammad Jibran
Definition and Classification *37*
Approach Considerations *38*
Physical Examination *40*
Baseline Laboratory Evaluation *41*

8. Renal Denervation Therapy for Resistant Hypertension: Possible Pathophysiological Reasons **45**
C Venkata S Ram
Blood Pressure Control Mechanisms and Sympathetic Nervous System *45*
Renal Sympathetic Activity and its Relationship to Sympathetic Nervous System *47*
Renal Afferent Sympathetic Activity *47*
Renal Efferent Sympathetic Activity *48*
Renal Sympathetic Denervation and Blood Pressure Regulation *48*

9. Device-based Therapies for Resistant Hypertension: A Status Update **51**
C Venkata S Ram, Mohsin Wali
Background Rationale for Device-based Therapy for Hypertension *51*
Renal Denervation Therapy in Patients with (Resistant) Hypertension *52*
Office/Clinic Blood Pressure Measurements versus Ambulatory Blood Pressure
Monitoring in Renal Denervation Therapy Trials *53*
Newer Techniques and Devices for Renal Denervation *53*
Baroreceptor Activation Therapy 54
Median Nerve Modulation 54
Central Arteriovenous Coupler Therapy for Resistant Hypertension 55

10. Obstructive Sleep Apnea and Resistant Hypertension **59**
Ajay Kumar Sinha, Pramod Kumar, Vikas Singh, Anand Gopal, Dina Nath, Shaheen Ahmad Sanjeev Kumar, Mridu Sinha
Historical Perspective 59

11. Advanced Lipid Testing: Who Needs It? **63**
BP Singh, Ravi Vishnu Prasad, Nishant Tripathy, Nirav Kumar
Basic Lipid Biology *63*
Components of Advanced Lipid Tests *64*
Advanced Lipid Test Methods *67*
When Advanced Lipoprotein Tests Used in Clinical Practice? *68*
Advanced Lipoprotein Analysis for Cardiovascular Disease Risk Prediction in Drug-treated Patients *68*
Who Should Receive Advanced Lipid Testing? *69*

12. Current and Future Therapeutic Options Targeting Cardiovascular Disease Risk: Emerging Therapies for Dyslipidemia Treatment **73**
Satyendra Tewari, Deep Chandh Raja S
Reduction of Low-density Lipoprotein Cholesterol *73*
Increase of High-density Lipoprotein Cholesterol *76*
Reduction of Triglycerides *76*
Strategies Targeting Lipoprotein (A) *77*

13. Management of Statin Intolerant High-risk Patients: What are the Current Options? **79**
AK Pancholia, Vidya Pancholia, Vijay Garg
What are the Risk Factors that can Cause Statin Intolerance? *80*
How to Identify Statin Intolerance? *80*
Evaluation of Statin Intolerance *81*
Management of Statin Intolerance *81*

14. Ezetimibe: Is There a Role in 2016? **87**
A George Koshy, PV Sanjai
Cholesterol Metabolism *87*
Mechanism of Action of Ezetimibe *87*
Pharmacokinetics *88*
Need for Ezetimibe *88*
Carotid Intima Media Thickness Enigma *90*
Clinical Outcome Trials *92*

SECTION 3 CORONARY ARTERY DISEASE

15. Burgeoning Role of Telemedicine in STEMI Interventions **99**
Sameer Mehta, Alexandra Ferré, Daniela Parra, Marco Castillo, Pablo Yépez Estefania Oliveros, Daniel Rodriguez
Methods *100*
Results *105*
Discussion *107*

16. How to Manage Bleeding following Thrombolysis? **111**
Uday B Khanolkar, Rajkumar Annamalai
Fibrinolytic Agents and Implication on Bleeding *111*
Classification of Severity of Bleeding *112*
Bleeding after Thrombolysis in Prior Trials *112*
Risk Factors for Bleeding *113*
Clinical Impact of Bleeding Complications *113*
Management of Bleeding *113*
Bleeding Related to Specific Systems *114*
Gastrointestinal Bleeding *114*

17. Protection of Microcirculation during PCI **117**
Rabin Chakraborty, Arindam Pande
No-reflow/slow-flow Phenomenon *117*
Therapeutic Options for Protecting Microcirculation during Percutaneous Coronary Intervention *118*

18. Medically Treated Acute Coronary Syndrome: Role of Antiplatelet **123**
Dhiman Kahali
Current Antiplatelet Medications *123*
Dual Antiplatelet Therapy and its Optimum Duration in ACS *125*
Studies on Shorter Duration of DAPT *125*
Studies on Longer Duration of DAPT *125*
Major Trials on Duration of DAPT in ACS *125*
Dapt Score: A Tool to Predict Duration of DAPT *126*
Platelet Function Testing *127*
Rationale for Switching Between Different Antiplatelet Medicines *127*

19. Primary Percutaneous Coronary Intervention in Resource Poor Setting **131**
Mahendra Prasad Tripathy, Panchanan Sahoo, Shishu Shankar Mishra
Bottlenecks in a Resource Poor Setting *131*
Early Diagnosis and Telemedicine *131*
Transportation *132*
National ST-elevation Myocardial Infarction India Programme Recommends *132*
Primary Percutaneous Coronary Intervention in Resources Poor Situation *132*

20. Cardiac Rehabilitation in Coronary Artery Disease **135**
JPS Sawhney, Saurabh Bagga, Kushal Madan
Evidence *135*
Current Model of Cardiac Rehabilitation *135*
Cardiac Rehabilitation in Patients with Coronary Bypass Graft Surgery *136*
Structure of Cardiac Rehabilitation *136*
Inpatient Cardiac Rehabilitation *137*
Outpatient Cardiac Rehabilitation *137*
Barriers and Challenges to Cardiac Rehabilitation *139*

SECTION 4 HEART FAILURE

21. Heart Failure in India: Need for Indian Guidelines **143**
Sandeep Seth
Status of Heart Failure in India *143*
Guidelines for Heart Failure in India *144*
Recommendations for Implantable Cardioverter Defibrillator *146*
Indications for Cardiac Resynchronization Therapy *146*
Cardiac Transplantation *146*

22. Lessons Learned from Trivandrum Heart Failure Registry **149**
S Harikrishnan

23. Evaluation and Management of Heart Failure in Patients with Reduced Ejection Fraction **153**
Amal Kumar Banerjee
Classifiction *153*
Diagnosis *154*
Pharmacologic Treatment *155*
Nonsurgical Device Treatment *156*
Mechanical Circulatory Support and Heart Transplantation *157*
Heart Failure and Comorbidities *157*
Arrhythmias and Conductance Disturbances *157*
Monitoring *157*

24. Outpatient Management of Patients with Left Ventricular Dysfunction: Balancing the Evidence-based Therapies **159**
Jamshed J Dalal
Types of Chronic Heart Failure *159*
Common Causes of Heart Failure *159*
Prevalence of Heart Failure *159*
Prognosis *159*
Investigations during Outpatient Visit *160*
Treatment *161*

Indications for Implantable Devices *163*
Lifestyle Modification *163*

25. Use ACE Inhibitors in Heart Failure with Renal Dysfunction **167**
Ajit Bhagwat
Angiotensin-converting Enzyme Inhibitors in Congestive Heart Failure and Chronic Kidney Disease *167*

26. Sodium Restriction in Heart Failure: What Should We Recommend? **173**
Saumitra Ray, Arghya Chattopadhyay
Pathophysiology of Heart Failure and Role of Sodium *173*
Standard Recommendation and Newer Controversy *174*

27. Neprilysin Inhibitors in Heart Failure **177**
RK Saran, Akhil Kumar Sharma, Vasudha Jain, Dharam Prakash Saran
Trial Evidence of ARNI in Heart Failure with Preserved Ejection Fraction *180*
Safety Concerns and Problems with use of Neprilysin Inhibitors *180*
Current Recommendations of ARNI in Heart Failure with Reduced Ejection Fraction *180*
Current Recommendations of ARNI in Heart Failure with Reduced Ejection Fraction *180*
ARNI: Beyond Heart Failure *180*

28. Heart Failure and Antithrombotics **185**
Mrinal Kanti Das
Epidemiology *185*
Pathobiology *186*
Recommendations *188*

29. Management of Heart Failure in Hypertrophic Obstructive Cardiomyopathy **191**
I Sathyamurthy, KN Srinivasan
Management *191*
Pharmacological Therapy *191*
Septal Reduction Techniques *193*

30. Autonomic Tone Modulation in Heart Failure **199**
Narayanan Namboodiri, Abhilash SP
Autonomic Nervous System *199*
Autonomic Tone Modulation in Heart Failure *200*
Autonomic Tone Modulation in Heart Failure with Preserved Ejection Fraction *200*
Therapeutic Modulation of Autonomic Tone in Heart Failure *200*

31. Stem Cells and Cardiac Regeneration in Heart Failure: Current Perspective **205**
Umesh C Samal, Jaideep Menon
Background to Stem Cells as a Treatment Modality *205*
Principles of Stem Cell Therapy *205*
Classification of Stem Cells *206*
Mechanism of Cardiac Regeneration with Stem Cells *208*
Applications: Acute Myocardial Infarction *213*
Chronic Ischemia *214*
Pharmacological Effects on Cell Therapy *215*
Diet, Exercise and Others *216*
Future Directions *216*

SECTION 5 PREVENTIVE CARDIOLOGY

32. Utility of Nontraditional Risk Markers in Atherosclerotic Cardiovascular Disease Risk Assessment **221**
P Venugopal, Kiran Jacob, A George Koshy
High Sensitive C-Reactive Protein *221*
Coronary Artery Calcium Score *221*
Lipoprotein (A) *222*
Ankle-Brachial Index *222*
Pentraxin 3 *223*
Carotid Artery Intima-Media Thickness *223*
Plasma Soluble Urokinase Plasminogen Activator Receptor *223*
Matrix Metalloproteinases *223*
Homocysteine *224*
Tissue Plasminogen Activator *224*
Small Dense Low-density Lipoprotein *224*
Fibrinogen *224*
Other Nontraditional Risk Markers *224*

33. Antiplatelets Beyond One Year for Secondary Prevention: Which Drug, When and Why? 227
JS Hiremath, KS Sheth
Evidence *227*
Summary and Conclusion of Evidence *228*
Discussion *228*

34. Central Hemodynamic Parameters as Additional Markers for Cardiovascular Risk Profiling 231
Kajal Ganguly, Pradip Ghoshal, Santanu De, Arindam Basu, Auriom Kar
Pulse-wave Velocity *231*
Central Aortic Blood Pressure *232*
Augmentation Index *232*
Measurement of Central Blood Pressure *232*
Subendocardial Viability Ratio *234*

35. Stress ECG: Interpretation Beyond ST Segment 237
SB Gupta
Measurement of Parameters in Computerized Stress Test *237*
Abnormal Variations of Parameters in Computerized Stress Test *237*
Scoring Systems *238*
Heart Rate *238*
ST Segment Elevation *239*

36. Epicardial Fat and Cardiovascular Risk 241
K Sarat Chandra, Manish Bansal
What is Epicardial Fat? *241*
Functional Properties of Epicardial Fat *242*
How is Epicardial Fat Quantified? *242*
Epicardial Fat as a CVD Risk Marker *244*
Epicardial Fat as a Therapeutic Target *246*

37. Perils of Sugar-sweetened Beverages 249
Geevar Zachariah, James KJ
Sugar, an Indian invention *249*
Dietary Sugars *249*
Consumption of Sugar-sweetened Beverages in India *250*
Obesity and Consumption of Sugar-sweetened Beverages *250*
Can Increased use of Sugar-sweetened Beverages Lead to Diabetes? *250*
What is the Relationship Between Increasing Use of Sugar-Sweetened Beverages and Cardiovascular Diseases? *250*
Other Metabolic Conditions *250*
Biological Mechanisms for the Adverse Effects of Sugar-Sweetened Beverages *251*
Healthy Alternatives to Sugar-sweetened Beverages *252*
How to Reduce Consumption of Sugar-sweetened Beverages? *252*
Recommendations *252*

38. Air Pollution and Cardiovascular Events 255
Sanjiv Bharadwaj, Mithilesh Kumar
Main Air Pollutants *255*
Air Pollution and Mortality *257*
Heart Failure *258*
Air Pollution and Blood Pressure *260*

39. Silent Information Regulator 2 Proteins: Sirtuins and Cardiovascular Disease 261
S Ramakrishnan, Danny Kumar
SIRT 1 *261*
SIRT 3 *262*
SIRT 6 *262*
SIRT 7 *262*
Human Studies of Sirtuins *262*
Pharmacological Modulation of Sirtuin Activity: Activating Drugs *262*

SECTION 6 INTERVENTIONAL CARDIOLOGY

40. Hemodynamic Assessment in the Cardiac Catheterization Laboratory: A Forgotten Art 267
Jaganmohan A Tharakan, Sanjay G
Before the Study *267*
How Invasive Studies add to Diagnosis and Management in the Contemporary ERA? *268*
Errors During Invasive Cardiac Catheterization *277*

41. How to Pre-empt Complications during PCI? **279**
A Jabir, Anoop Mathew, Rony Mathew
Contemporary Complications Rates of PCI (NY State PCI Registry) *279*
To Prevent Complications in General *280*
Team Work, Protocols, Checklist *280*
Indication *280*
Risk Stratification *280*
Operator Fatigue *280*
Preventive Measures of Common Complications *281*
Threatened Coronary Artery Closure *281*
Iatrogenic Coronary Artery Dissection *281*
Preventing Dissection Tips *281*
Coronary Artery Perforations *283*
Risk Factors for Coronary Perforation *283*
Thrombus Formation *284*
How to Prevent Inadvertent Thrombus Formation during PCI? *284*
Air Embolism *284*
How to Prevent? *284*
Retained Equipment *284*
How to Avoid? *285*
No Reflow *285*
Vascular Injury *285*
Contrast-induced Acute Kidney Injury (Ci-AKI) *285*
To Prevent *285*
The Golden Rules to Prevent Complications *286*

42. Multivessel Percutaneous Coronary Intervention in Acute Myocardial Infarction: The Current Views **287**
Kirti Punamiya
Past Trials and Data *287*
Current Trial and Prospective Data *288*
Discussion *289*

43. Bifurcation Stenting: Matching Strategy to the Lesion **293**
Brian Pinto, Ankeet Dedhia
Definition and Classification *293*
Fundamental Aspects *294*
Planning the Procedure: One or Two-stent Technique *294*
Provisional Technique *295*
Proximal Optimization Technique *295*
Difficult Side Branch Rewiring *296*
Kissing Balloon Inflations in Simple Single Stenting *296*
Use of Noncompliant Balloons for Kissing *296*
Provisional Stenting of the Side Branch *296*
Planned Two-Stent Techniques *297*
Various Two-Stent Techniques *297*
T-stenting Techniques *299*
V-stent and Simultaneous Kissing Stents Technique *300*
Optimizing Kissing Balloon Inflation in Two-Stent Techniques *300*
Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting For Distal Left Main Bifurcation Lesions *300*
Percutaneous Coronary Intervention of the Unprotected Distal Left Main Coronary Artery Bifurcation *300*
Two-Stent Techniques for Left Main Coronary Artery Bifurcation Treatment *301*
Adjunctive Intracoronary Imaging in Bifurcation Treatment *301*
Use of Fractional Flow Reserve in Bifurcations *302*
Dedicated Bifurcation Stent Systems *303*

44. Orbital Atherectomy **307**
Samin K Sharma, Matthew I Tomey
Introduction: the Dual Dilemma of Calcified Plaque *307*

45. Consequences of Unsuccessful versus Successful Chronic Total Occlusions Interventions **315**
PK Goel
Why to do CTO Intervention: The Benefits of Successful CTO-PCI? *315*
Consequences of Unsuccessful CTO-PCI *318*

46. Uses of Optical Coherence Tomography in Special Situations **323**
G Sengottuvelu
Preprocedural Lesion Assessment *323*
Miscellaneous *331*

47. Multivessel Percutaneous Coronary Intervention: When and How? **333**
Sreenivas Kumar Arramraju, Vuppaladadhiam Hariram
Decision Making Protocol in Multivessel Disease *333*
Clinical Presentation *333*

48. Fractional Flow Reserve: Current Strategies for Complex Interventional Subsets **337**
DS Chadha, SK Malani
Anatomical Complete Revascularization *337*
Functionally Complete Revascularization *338*
Left Main Coronary Artery Disease *338*
Multivessel Disease *339*
Bifurcation Disease *339*
Tandem Lesions *339*
Diffuse Coronary Artery Disease *340*
Collateral Blood Flow *340*
End Point of Percutaneous Coronary Intervention *340*

49. How to Manage Coronary Perforation? **343**
CN Makhale, Salil Vaidya, Hammad Momin
Classification of Coronary Perforation *343*
Risk Factors *343*
Sequel of Coronary Artery Perforation *343*
Prevention *344*
Diagnosis *344*
Management *344*

50. Stent Thrombosis: Current Understanding **347**
Prasant Kumar Sahoo, Biswaranjan Jena, Nirmal Kumar Mohanty
Stent Thrombosis *347*
Classification of Stent Thrombosis (Academic Research Consortium) *347*
Timing of Stent Thrombosis *347*
Incidence of Stent Thrombosis *347*
Procedural Factors *350*
Antiplatelet Regimens and their Role in Stent Thrombosis *351*
How to Minimize Stent Thrombosis? *353*

51. Current Status of Drug-coated Balloons **357**
Mukund A Deshpande, Sunil N Washimkar, Rohan Parikh
Mechanism of Action *357*
Types *358*
Preclinical Data *358*
Clinical Data *359*

52. Biodegradable Polymers and Polymer-free Drug-eluting Stents: Do they Represent a Meaningful Advantage? **365**
Nakul Sinha, Himanshu Rai, Salvatore Cassese
Role of Polymer Coatings as Envisaged Initially *365*
Polymer Coatings and Drug-release Kinetics *365*
Preliminary Data with Earlier Durable Polymer Coatings *366*
Why Durable Polymer Coatings Came in Disrepute? *366*
Biodegradable Polymer Drug-Eluting Stents and Potential Advantages of this Technology *367*
Polymer-free Drug-eluting Stents and Potential Advantages of this Technology *368*
Clinical Results of Polymer-free Drug-eluting Stents Outside the Randomized Trials *369*

53. Stent Design: What You Must Know? **375**
Vijay Bang
Tail-wire (Szabo) Technique *376*
Backstop Technique *377*

54. Ruptured Sinus of Valsalva: No More a Surgical Domain? **383**
Prafulla G Kerkar, Jivtesh S Pahwa, Rishi A Bhargava
Epidemiology and Etiopathogenesis *383*
Presentation and Natural History *383*

Imaging for Transcatheter Closure of Ruptured Sinus of Valsalva *384*
Transcatheter Closure of Ruptured Sinus of Valsalva *385*
Surgery Versus Transcatheter Closure *387*

55. Endovascular Interventions for Takayasu Arteritis **389**
Narendra Nath Khanna, Rini Pramesti, Emmanuel Auchi Edafe, Peter Dodo Yakubu, Obiora Ajuluchukwu, Suparna Rao
Epidemiology *389*
Etiology *389*
Pathology and Clinical Manifestations *389*
Diagnosis and Classification *390*
Medical Management *392*
Surgery *393*
Endovascular Intervention *393*
Optimizing Outcome of Endovascular Intervention *397*

56. Renal Artery Stenosis: To Fix or Not to Fix **401**
Sanjay Tyagi, Ankit Bansal, Dhruv Tyagi
Clinical Clues to the Diagnosis of Atherosclerotic Renal Artery Stenosis *401*
Diagnosis of Renal Artery Stenosis *401*
Management of Renal Artery Stenosis *402*
Medical Treatment *402*
Revascularization Surgical Therapies *402*
Percutaneous Transluminal Renal Artery Angioplasty *402*
Selecting Patients Likely to Benefit from Percutaneous Transluminal Renal Artery Angioplasty ± Stenting *403*
Recent Clinical Trials in Atherosclerosis *404*

57. Clinical Scenarios in Carotid Stenting **409**
Atul Mathur, Gaurav Bhardwaj, Pradeep E Harnahalli
Bilateral Carotid Stenosis *409*

58. Mesenteric Ischemia **413**
Tarun Madan
Mesenteric Ischemia *413*
Acute Mesenteric Ischemia *414*
Chronic Mesenteric Ischemia *417*

SECTION 7 ELECTROPHYSIOLOGY

59. Early Repolarization Syndromes **423**
Ajay Naik
Historical Perspective *423*
Pathophysiology *423*
Clinical Perspectives and Risk Stratification *424*
Therapeutic Interventions *426*
Future Perspectives *427*

60. Diagnostic Evaluation of Cardiac Syncope **429**
Narayan Chandra Sarkar, Piyabi Sarkar
Causes of Syncope *429*
Pathophysiology of Cardiac Syncope *429*
Diagnostic Test in Evaluation of Syncope *430*
History and Physical Examination *430*
Echocardiography *430*
Holter Monitoring *430*
Evaluation of Automatic Dysfunction *430*
Signal-Average Electrocardiogram *431*
Loop Recorder *431*
Invasive Tests *431*
Site of Block *431*
Tachycardia with Narrow QRS Complex *431*
Tachycardia with Broad QRS Complex *432*
Wolff-Parkinson-White Syndrome *432*
Evaluation of Unexplained Syncope *432*
Evaluation of Cardiac Arrest Survivors *433*

Evaluation of Palpitations *433*
Electrophysiological Guidelines of Drug Therapy *433*

61. Pacemaker Lead Extraction: A Growing Need **435**
Archana Rao, Renjith Antony
Scale of the Problem *435*
Indications *435*
Contraindications *436*
Lead Removal Procedure *437*
Complications *438*
Device Replacement *438*

62. Role of CRT in RBBB and Narrow QRS **441**
Ulhas M Pandurangi, G Anitha Sathishkumar
Cardiac Resynchronization Therapy in Right Bundle Branch Block *441*
Cardiac Resynchronization Therapy in Narrow QRS *443*

63. Wearable Cardioverter Defibrillator **445**
Ravi Kishore Amancharla, S Ramakrishnakumar
Limitations of Implantable Cardioverter Defibrillators *445*
Wearable Cardioverter Defibrillator *446*
Observational Studies with Wearable Cardioverter Defibrillator *446*
Indications for Wearable Cardioverter Defibrillator Therapy *449*
Advantages of Wearable Cardioverter Defibrillator Over Implantable Cardioverter Defibrillators *450*
Complications of Wearable Cardioverter Defibrillator Use *450*
Relative Contraindications for Wearable Cardioverter Defibrillator Use *450*
Future Perspective *450*
Ongoing Trials *450*

64. When Should We Consider Automatic Implantable Cardiac Defibrillator after Myocardial Infarction? **453**
KK Talwar, Abhinit Gupta
Review of Indications of Automatic Implantable Cardiac Defibrillator after Myocardial Infarction *453*
Sudden Cardiac Death Risk Early after Myocardial Infarction *454*
Late Sudden Cardiac Death Risk (>40 days) after Myocardial Infarction *454*
Evidence in Light of Practical Implications *455*
Need for Additional High-risk Sudden Cardiac Death Indicators (Beyond Left Ventricular Ejection Fraction) *455*
Role in the Era of Revascularization *455*
So, When to Consider Implantable Cardiac Defibrillator after Myocardial Infarction? *456*

65. Value and Limitations of Echocardiography for Dyssynchrony and Cardiac Resynchronization Therapy **461**
Yash Lokhandwala, Aniruddha Vyas, Neeta Bachani
Cardiac Dyssynchrony *461*
Role of Echocardiography in Cardiac Resynchronization Therapy Selection *462*
Presently Available Echocardiographic Assessment for Intra-LV Dyssynchrony *462*
Which Echocardiographic Techniques are Better? *465*
Present State of Echo in Cardiac Resynchronization Therapy Case Selection: Aftermath of Prospect Trial *465*
Do All Left Ventricular Dysfunction Patients with >*150* ms QRS Left Bundle Branch Block Need Cardiac Resynchronization Therapy Despite no Echocardiographic Dyssynchrony? *468*
Cardiac Resynchronization Therapy in Patients with Echocardiographic Dyssynchrony with QRS <150 ms *468*

66. Biological Pacemakers **471**
Aditya Kapoor, Paurush Ambesh
Limitations of Current Electronic Pacemakers *471*
Single and Dual Gene-based Therapy Targeting Ionic Channels *474*

SECTION 8 ATRIAL FIBRILLATION

67. Stroke Prevention in Atrial Fibrillation: Opportunities and Challenges **481**
GR Kane, Ankur Jhavar, Mukesh Laddha
Vitamin K Antagonist *481*
Stroke Risk Stratification *481*
Bleeding Risk Assessment *482*
Oral Anticoagulant Clinic *483*
Home Monitoring *483*
Newer Oral Anticoagulants *483*

Rationale for Left Atrial Appendage Occlusion *485*
Available Devices *485*

68. NOACs in NVAF: Challenges in India and Real World **489**
HK Chopra, Pawan Kumar Sharma, RS Sambi, CK Krishna, Harmeet Singh
Thrombin (Factor IIA) Inhibitors *489*
Factor XA Inhibitors *491*
Bleeding Risk with Novel Oral Anticoagulants Due to Drug-drug Interactions *494*
Monitoring Anticoagulation with Novel Oral Anticoagulants *494*
Periprocedural Management *494*
Switching from Novel Oral Anticoagulants to Other Anticoagulants *496*
Management of Bleeding Associated with Novel Oral Anticoagulants *496*
Potential Clinical Uses of Novel Oral Anticoagulants *497*
Situations to be Cautious with Novel Oral Anticoagulants *497*
Which Oral Anticoagulant Should I Choose? *497*

69. Ablation for Atrial Fibrillation: Current Status **503**
Ashish A Nabar, Devendra V Patil
Clinical Basis for Atrial Fibrillation Ablation *503*
Pathological Basis of Atrial Fibrillation Ablation *503*
Atrial Fibrillation Ablation Strategies *504*
Energy Sources for Atrial Fibrillation Ablation *506*
Periprocedural Imaging *507*
Anticoagulation Policy *507*
Procedural Success *507*
Complication and Recurrence *508*

SECTION 9 VALVULAR HEART DISEASE

70. Paravalvular Leaks: Current Management Concepts **513**
K Sivakumar
Interventional Management of Paravalvular Leak *513*
Why Should Paravalvular Leaks be Closed? *513*
What are the Risks in a Redo Surgery? *514*
Recurrences after Surgery *514*
Limitations of Imaging Techniques *514*
Role of Fluoroscopy *514*
Sizing the Paravalvular Leak *514*
Care to Avoid Crossing the Prosthetic Valve Orifice *515*
Choice of Devices Available for Paravalvular Leak Closure *515*
Newer Dedicated Devices *516*
Hybrid Surgical Approaches *516*
Key Procedural Steps *517*
Device Placement in the Leak *517*
Postprocedural Assessment *517*
Indicators of Success *518*
Echo Integration *518*
Computed Tomography Navigator *519*

71. Mechanical Heart Valves and Pregnancy **521**
G Karthikeyan
Prosthetic Heart Valves and Thromboembolism *522*
Pregnancy in Association with Prosthetic Heart Valves *522*
New Direct Acting Anticoagulants *522*
Dabigatran *523*
Current Guideline *523*
Warfarin *523*
Bioprosthetic Valves *523*
Unfractionated Heparin *524*

72. Secondary (Functional) Mitral Regurgitation: Evaluation and Management **527**
Satyavan Sharma, Nikhil Raut
Pathophysiology *527*
Incidence and Prognostic Considerations *528*

Evaluation *528*
Therapeutic Considerations *530*

73. Technically Challenging Percutaneous Balloon Mitral Valvuloplasty **533**
BC Srinivas, Vijaykumar JR, CM Nagesh, Babu Reddy, KH Srinivas, KS Ravindranath, CN Manjunath
Indications *533*
BMV Technique *534*
Transseptal Puncture *534*
Landmarks for Transseptal Puncture *534*
Technique of Transseptal Puncture *535*
Methods of Crossing the Mitral Valve *535*
Technically Difficult Situations/Complex Anatomy *536*

74. Transcatheter Mitral Valve Therapy: Hope Beyond Hype **551**
Smit Shrivastava
Classification of Mitral Regurgitation *551*
Anatomy of Mitral Valve *551*
Annulus *552*
Leaflet *554*
Chordae Tendineae *556*
Papillary Muscles and Left Ventricle *556*

75. Asymptomatic Severe Aortic Stenosis: When to Intervene? **561**
Madhusudan Borde
Pathophysiology of Aortic Stenosis *561*

76. Treatment of Aortic Stenosis using Percutaneous Valve, Indications, Selection, Step-by-step Procedure of Transcatheter Aortic Valve Replacement **567**
Sanjay Mehrotra, Ujjwal Chand Mehrotra, BK Mahala
Who Needs Treatment? *567*
Planning and Patient Assessment *568*
Procedure *568*
Preparation of Valve *569*
Temporary Pacemaker *569*
Implantation of Valve *569*

SECTION 10 CONGENITAL HEART DISEASES

77. Hematological Abnormalities and their Management in Adults with Cyanotic Congenital Heart Diseases **573**
IB Vijayalakshmi
Physiologic Response to Chronic Hypoxemia *573*
Hematological Abnormalities *574*
Hemostatic Abnormalities *576*
Risk Reduction Strategies *577*
Special Precautions for Laboratory Testing *577*

78. Interventions to Create Interatrial Septal Communications **579**
K Sivakumar
Indications *579*
Vascular Access *580*
Morphology of Atrial Septum *581*
Balloon Atrial Septostomy *581*
Caution during Septostomy *581*
Success of Septostomy *582*
Controlled Over the Wire Septostomy *582*
Static Balloon Septoplasty *582*
Blade Septostomy *582*
Initial Steps before Septal Puncture *582*
Septal Puncture *583*
Echocardiographic Guidance for Septal Puncture *583*
Choice of Stent for Atrial Septum *583*
Role of Echocardiography *584*
Stenting on Echocardiographic Guidance *584*
Complications after Stenting *584*
Newer Devices for Atrial Communications *585*

79. Congenital Heart Disease and Pregnancy: An Indian Perspective **587**
Anita Saxena
Introduction and Scope of the Problem *587*
Hemodynamic Changes during Pregnancy, Delivery and Postpartum Period *587*
Diagnosis of Heart Disease during Pregnancy *588*
Complications in the Offspring due to Maternal Congenital Heart Disease *588*
Recurrent Risk of CHD in Offsprings *589*
Risk Assessment in Mothers with Congenital Heart Disease *589*
Management of Pregnancy in Women with Congenital Heart Disease *590*
Specific Conditions at High-risk *591*

80. Fetal Cardiac Interventions **595**
Nageswara Rao Koneti, Saileela R
Progression of Cardiac Lesions In Utero *595*
Development of Fetal Cardiac Interventional Program *597*
Procedure *597*
Complications of Fetal Cardiac Interventions *600*

SECTION 11 PULMONARY HYPERTENSION

81. Prognostic Indicators Pulmonary Thromboembolism **605**
Aziz Khan, Kashif Syed, Navneet Wadhwa
Need for Prognostic Markers *605*
Pathophysiology of Pulmonary Embolism *605*
Parameters for Diagnosis, Evaluation and Prognosis *606*
Evidence is Emerging and Evolving *609*
Approach Considerations *609*
Thrombolysis *609*
Anticoagulation *610*

82. Thrombolytic Therapy for Pulmonary Embolism: Indications, Regimen and Outcomes **613**
SK Malani, Balbir Singh, DS Chadha
Risk Stratification in Acute Pulmonary Embolism *613*
Role of Thrombolytic Therapy for Acute Pulmonary Embolism *616*
Evidence for Thrombolysis for Acute Pulmonary Embolism *616*
Selection of Thrombolytic Agent in Pulmonary Embolism *617*
Role of Local/Catheter Directed Thrombolysis *617*

83. Pulmonary Artery Denervation in Severe Pulmonary Hypertension: Concept and Results **621**
B Ramesh Babu, Pankaj Jariwala
Autonomic Nervous System and Heart *621*
Previous and Current Treatments Targeting Cardiovascular Sympathetic System *621*
Pathophysiology of Pulmonary Artery Hypertension *622*
Method of Pulmonary Artery Denervation *624*
Animal Studies *625*
Pilot Study of Pulmonary Artery Denervation *628*
Other Studies of Pulmonary Artery Denervation *629*
Limitations of PADN and its Present Studies *630*

84. Cor Pulmonale **633**
Shishu Shankar Mishra, Biswaranjan Mishra, Gitanjali Kar, Satyanarayan Routray, Pradeep Kumar Behera
Epidemiology *633*
Etiology and Pathophysiology *633*
Clinical Presentation *634*
Diagnosis *634*
Management *638*
Prognosis *639*

85. Right Ventricular Function: A Grossly Neglected Entity **643**
Geetha Subramanian, Balaji Lohiya, Vikas Agrawal, Omshankar
Anatomy and Pathophysiology *643*
Clinical Manifestation *645*
Clinical Importance of RV Function *645*
Echocardiographic Assessment *647*

3D Imaging and RV *648*
Magnetic Resonance Imaging *648*
RV Function Assessment and Interventricular Septum *648*

SECTION 12 ECHOCARDIOGRAPHY AND IMAGING

86. Stress Evaluation: Valvular Heart Diseases **653**
Sameer Shrivastava, Arif Mustaqueem
Who with Valvular Heart Disease Requires Stress Echo Evaluation *653*
Protocols of Stress Echocardiography *655*
Reporting System in Stress Echo in Valvular Heart Disease *655*
Clinical Implications of the Results *655*
Current Guidelines *657*

87. Pitfalls in Assessment of Stenotic Lesions **661**
Satish K Parashar, Sameer Gupta, Sujeet Narain
Mitral Stenosis *661*
Aortic Stenosis *664*

88. How to Evaluate Mitral Regurgitation on Echocardiography? **669**
CK Ponde, Maulik Parekh
Mitral Valve Anatomy *669*
Mechanism of Mitral Regurgitation *670*
Functional Mitral Regurgitation: Secondary MR *671*

89. Role of Dobutamine Stress Echocardiography in Assessment of Myocardial Viability **681**
Nitin J Burkule
Pathophysiology of Myocardial Dysfunction in Ischemia *681*
Methods to Detect Viability *682*
Late Gadolinium Enhancement on Magnetic Resonance Imaging *683*
Newer Echocardiographic Modalities for Detection of Viability *685*
Clinical Algorithm for Myocardial Viability Assessment *686*

90. Advantages of 3D Echocardiography in the Assessment of Cardiac Chambers **689**
Ravi R Kasliwal, Hardeep Kaur Grewal, Manish Bansal
Left Ventricle Assessment *689*
Right Ventricle Assessment *692*
Left Atrial Assessment *693*
Limitations of 3DE *694*

91. Clinical Implications of Left Atrium and Left Atrial Appendage Imaging **699**
HM Mardikar, Parag Admane
Left Atrium Size *699*
Left Atrial Appendage *700*
Cardiac Computed Tomography *701*
Left Atrium Function *703*
Doppler Evaluation of Left Atrial Appendage Function *704*

92. Utility of Coronary Computed Tomography Angiography for Suspected Coronary Artery Disease **707**
Jonathan Christopher
Role of Coronary Calcium Score (Noncontrast scan) *707*
Role of Computed Tomography Coronary Angiography (Contrast Scan) *708*
Limitations of Coronary CTA *708*
Diagnostic Accuracy of Coronary CTA *709*
Prognosis after Coronary CTA *709*
Impact of Coronary CTA on Patient Management and Outcomes *711*
Cost-effectiveness of Coronary CTA in Suspected Coronary Artery Disease *711*
Coronary CTA in the Evaluation and Management of Acute Coronary Syndrome *711*

93. Multimodality Imaging in Hypertrophic Obstructive Cardiomyopathy **715**
Soumitra Kumar, Md Saiyed Rana
Prevalence *715*
Genetics *715*
Natural History *715*
Why Cardiac Imaging is so Important in Hypertrophic Cardiomyopathy? *716*
What is the Information Provided by Cardiac Imaging? *716*

94. Fractional Flow Reserve Computed Tomography: Ready Prime Time **723**
Suman Bhandari, Sujit Sawadatkar, Milan Bhardwaj
CT Coronary Angiography *724*
Limitation of CTCA and its Solution *724*
CT FFR: Estimating Lesion-specific Ischemia from Resting CT Angiography *725*
FFRCT Scientific Evidence *726*
Discover-flow Study *726*
DeFACTO Study *726*
NXT Study *727*
Platform Study *727*
Single Center Study *728*
Promise Trial *728*
Future Studies *728*
FFRCT Testing and Present Status *728*
Strengths *728*
Limitations *730*

SECTION 13 CARDIOVASCULAR THERAPEUTICS

95. Glycoprotein IIb/IIIa Inhibitors: Have they become Obsolete? **735**
PP Mohanan, Julian Johny Thottian, Binjo J Vazhappilly
Era of Clopidogrel in Moderate Doses *735*
Era of High Dose Clopidogrel and Newer Antiplatelets *735*
What is the Role of a Prolonged Infusion of GPIs after Primary PCI? *736*
What does the Guidelines say to Conclude? *737*

96. Drug Interaction in Cardiovascular Practice: Role of CYP 450 **739**
Tiny Nair
CYP Inhibitors and Select Drugs *741*

97. Cardiac Myosin Activators in Heart Failure **745**
Niteen V Deshpande, Mohan Deshpande
Concept of Cardiac Myosin Activators and Mechanism of Action *745*
Preclinical Studies *746*
Studies in Humans *746*
Studies in Systolic Heart Failure *746*
Study in Ischemic Cardiomyopathy *746*

98. PCSK9 Inhibitors **749**
Ajay Mahajan
Mechanism of Action *749*
Development of PCSK9-inhibiting Antibodies *749*
Effect of PCSK9-inhibiting Antibodies *751*
Effects on Lipids *751*
Clinical Efficacy *751*
Safety *752*
Indications and Future Perspectives *752*

How Do I Use?

99. Levosimendan **757**
Vidyut Jain, Avani Jain
Clinical Trials with Possible Indications for Levosimendan *757*
Dosage Guideline for Acute Decompensated Heart Failure *758*
Other Possible Indications *758*
Place in Clinical Practice *759*

100. Ferric Carboxymaltose **761**
Pradeep P Deshmukh, Amey Beedkar
Choice of IV Formulation *761*
Dose Calculation *762*
Managing Adverse Reactions *762*
Response Assessment *762*

101. Ivabradine **765**
Trinath Kumar Mishra, Biswajit Das, Sura Kishora Mishra, Shishu Sankar Mishra
Ivabradine in Coronary Artery Disease *765*

Mechanism *767*
Beneficial Effects *767*

102. Trimetazidine **769**
Sadanand R Shetty, Sadita S Shetty
Mechanism of Action *769*
Clinical Trials *770*
Guidelines Recommendations *771*

103. Tolvaptan **773**
A Ganguly
Clinical Situations *773*
Management *775*
Uses of Tolvaptan *775*

104. Endothelin Receptor Antagonists **779**
M Somasundaram, C Elamaran
Mechanism of Action *779*
Drug Interactions *780*
Drug Trials *781*
Side Effects *782*
Indications and Usage *782*
Dosage and Administration *783*

105. Saroglitazar **785**
SC Manchanda
Preclinical and Clinical Development of Saroglitazar *785*
Expert Opinion *786*

106. L-Carnitine **789**
Prasant Kumar Sahoo, Priyadarsi Tripathy, Nirmal Kumar Mohanty
Source and Daily Requirement *789*
Synthesis *789*
Function *789*
Carnitine Deficiency *790*
L-Carnitine and Heart Function *790*
L-Carnitine and Myocardial Infarction *790*
L-Carnitine and Congestive Heart Failure *791*
L-Carnitine and Cardiomyopathy *791*
Meta-analysis Review *791*
Indications for the Use of L-carnitine *792*
Other Potential Applications of L-carnitine *792*

107. Ranolazine **795**
Satyanarayan Routray, Chhabi Satpathy, SS Mishra
Mechanism of Action *795*
Drug Trials *796*
Summary of the Drug Trials *798*
Guideline Approved Indications *798*
How to Use the Drug? *799*
Adverse Effects *799*
Contraindications *799*
Drug Interaction *799*
Ranolazine in Indian Scenario *799*

108. Flecainide **803**
VS Narain, Gaurav Chaudhary, Dharam Prakash Saran
Clinical Pharmacology *803*

SECTION 14 MISCELLANEOUS

109. An Update on Kawasaki Disease **811**
Asha Moorthy, T Kallarakkal Jain
Epidemiology *811*
Etiology *811*

Pathology *811*
Clinical Presentations and Diagnosis *812*
Cardiovascular Manifestations of Kawasaki Disease *812*
Management *813*

110. Athlete's Heart **815**
Rajiv Bajaj
Physical Findings *815*
Laboratory Findings *815*
Physiology *816*
Pathophysiology *816*
Remodeling *817*
Ejection Fraction *817*
Diastolic Function *818*
Performance-enhancing Drugs *818*
Long-term Performance *818*

111. Management of Patients Undergoing Noncardiac Surgery after Coronary Revascularization **821**
V Dayasagar Rao, Mohammed Sadiq Azam
Classification of the Surgery According to Risk *821*
Noncardiac Surgery in Patient Postcoronary Revascularization *822*
Dual Antiplatelet Therapy after Coronary Stenting *822*
Issues of Stent Thrombosis *823*
Preoperative Assessment of Risks *825*
Preoperative Investigations *825*
Timing of Elective Noncardiac Surgery in Patients with Previous CABG/PCI *827*
Perioperative Antiplatelet Therapy *829*
Other Perioperative Risk Reduction Strategies *832*
Intraoperative and Postoperative Monitoring of Patients *833*

112. Mitochondrial Cardiomyopathy **837**
Siddharth Gadage
Cardiac Presentation of Mitochondrial Disease *839*
Mitochondrial Dysfunction in Acquired Heart Disease *839*

113. Cardiovascular Implications of Hypoglycemia **843**
PC Manoria, Pankaj Manoria, Piyush Manoria, SK Parashar
Clinical Outcomes in Patients with Severe Hypoglycemia *844*
New Oral Antihyperglycemic Agents and Hypoglycemia *845*

114. Cardioprotection During Chemotherapy **847**
Gurpreet S Wander, Abhishek Goyal, Ravina Sharma, Praneet Wander
Mechanism of Cardiotoxicity *847*
Strategies of Cardioprotection for Anthracycline Therapy *848*
Strategies of Cardioprotection for Nonanthracycline Therapies *851*

115. Emotions, Sexual Disorders, and the Heart **855**
Abhinav Tandon, Nagaraj Desai, TS Sathyanarayana Rao, Sunil Kumar S, Manjappa M, Prashanth Kulkarni
Brain, Emotions and Sexual Functioning *855*
Human Sexuality and Drugs *856*
Statistics: Sexual Dysfunction and Cardiovascular Comorbidity *856*
Management of Sexual Problems in General *857*

116. Identification and Management of Idiopathic Ventricular Tachycardia **865**
C Narasimhan, Ajit Thachil
Classification *865*
Prognosis *865*
Identification of IVT *866*
Identification of Structural Normalcy of the Heart *866*
Classification of IVT *867*
Mechanism of IVT *868*
Management of IVT *869*

Index *873*